title: Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein.
abstract: Human epidermoid KB cell lines resistant to high levels of adriamycin, C-A90, C-A120, C-A500, and C-A1000, were isolated in selection medium containing increasing concentrations of adriamycin, 1 microgram/ml of cepharanthine, a multidrug-resistance (MDR) reversing agent, and 100 nM of mezerein, a protein kinase C activating agent. One of the adriamycin-resistant KB cell lines, C-A500, was cross-resistant to drugs that typify the classical multidrug resistance phenotype, such as vincristine, actinomycin D, VP-16, and colchicine. The accumulation of adriamycin and vincristine was decreased in C-A500 cells and the efflux of adriamycin from C-A500 was enhanced compared with parental KB-3-1 cells. These adriamycin-resistant KB cells did not contain detectable levels of P-glycoprotein or overexpress MDR1. Multidrug-resistance-associated protein (MRP) and MRP mRNA were expressed in the adriamycin-resistant KB cells, C-A120, C-A500, and C-A1000, but not in parental KB-3-1 and revertant C-AR cells. The MRP gene was amplified in all the MDR cells that overexpressed MRP mRNA. DNA topoisomerase II levels were markedly decreased in C-A500 and C-A1000 cells but only slightly decreased in C-A120 cells. These results indicate that MRP overexpressed in the resistant cells may be responsible for the reduced accumulation of adriamycin and vincristine and that both the increased expression of MRP and decreased levels of topoisomerase II underlie the drug resistance in C-A120, C-A500, and C-A1000 cell lines.
authors: Department of Cancer Chemotherapy, Faculty of Medicine, Kagoshima University, Japan.
authors: T
authors: T
authors: Sumizawa
authors: Y
authors: Y
authors: Chuman
authors: H
authors: H
authors: Sakamoto
authors: K
authors: K
authors: Iemura
authors: K C
authors: KC
authors: Almquist
authors: R G
authors: RG
authors: Deeley
authors: S P
authors: SP
authors: Cole
authors: S
authors: S
authors: Akiyama
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D000470:Alkaloids / Q000494:pharmacology; D044182:Benzylisoquinolines; D002462:Cell Membrane / Q000737:chemistry; D002469:Cell Separation / Q000379:methods*; D003470:Culture Media; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis; D004224:Diterpenes; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D004591:Electrophoresis, Polyacrylamide Gel; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D015151:Immunoblotting; D012333:RNA, Messenger / Q000096:biosynthesis; D013729:Terpenes / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D052117:Benzodioxoles
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids; D044182:Benzylisoquinolines; D003470:Culture Media; D004250:DNA Topoisomerases, Type II; D004224:Diterpenes; D004317:Doxorubicin; D006023:Glycoproteins; D012333:RNA, Messenger; D013729:Terpenes; C011309:mezerein; C006947:cepharanthine; D052117:Benzodioxoles